Evidence analysisNovember 10, 2026Health & Science

Human medicines European public assessment report (EPAR): Herwenda, trastuzumab, Date of authorisation: 15/11/2023, Revision: 4, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

FreedomWitness Evidence Article: Evaluation of Herwenda (trastuzumab biosimilar) by EMA

What is established

Herwenda is a biosimilar medicine containing trastuzumab, authorised for use in the European Union since November 2023. It is intended to treat HER2-positive cancers, specifically early and metastatic breast cancer and metastatic gastric cancer. The medicine works as a monoclonal antibody targeting the HER2 protein, which is overexpressed in approximately 25% of breast cancers and 20% of gastric cancers. By binding to HER2, Herwenda activates immune responses to kill tumor cells and inhibits signals promoting tumor growth.

Herwenda’s similarity to the reference biological medicine, Herceptin (also trastuzumab), has been comprehensively evaluated. Laboratory analyses confirm it has a highly similar structure, purity, and biological activity. Pharmacokinetic studies demonstrate comparable levels of active substance in the body between Herwenda and Herceptin. A pivotal clinical study with 807 early HER2-positive breast cancer patients showed equivalent efficacy: about 47-48% of patients had no detectable actively growing cancer cells in tissue removed during surgery after treatment with either medicine.

The European Medicines Agency (EMA) concludes that Herwenda’s safety and effectiveness closely match Herceptin’s profile, with common side effects including heart problems, infusion-related reactions, blood cell reduction, infections, and lung issues. The recommended usage involves intravenous infusions typically every 1-3 weeks, with treatment duration varying based on cancer type and stage.

What the source claims

  • Herwenda is authorised under the EU regulatory framework for biosimilars, meeting all criteria for similarity to the reference product.
  • Clinical evidence supports Herwenda as an effective alternative to Herceptin for approved cancer indications, with no clinically meaningful differences in safety or efficacy.
  • The medicine’s approval is based in part on the principle that full re-evaluation of all clinical data on trastuzumab is unnecessary, as similarity to the original product implies similar treatment outcomes.
  • Safety monitoring of Herwenda will continue post-authorisation, including evaluation of adverse event reporting.
  • Herwenda should be prescribed and administered by healthcare professionals experienced in anticancer therapies.

What may be missing from the usual framing

The EMA summary does not elaborate on comparative cost implications or access equity between Herwenda and Herceptin. While biosimilars often aim to increase treatment affordability and availability, the report does not discuss pricing, reimbursement, or potential uptake barriers within different EU countries.

Furthermore, while clinical studies confirm equivalence of primary efficacy endpoints and safety within controlled trial settings, longer-term real-world effectiveness and rare adverse events may not be fully captured at the time of approval. Post-market surveillance is essential but details on specific risk mitigation strategies or registries are limited in the source.

The information focuses on biological and clinical similarity with no discussion of manufacturing quality variation, supply chain considerations, or potential immunogenicity differences, which have been concerns raised in other biosimilar contexts.

Competing evidence or uncertainty

Evidence in this dossier is primarily from the EMA’s official medicines assessment and linked clinical studies. Independent peer-reviewed studies or meta-analyses evaluating Herwenda specifically were not cited, so broader academic validation is not documented here.

Uncertainty remains regarding the equivalency of Herwenda in diverse patient populations with co-morbidities, varying cancer subtypes, or in combination with different chemotherapy agents beyond those tested in controlled trials. Equivalence is inferred on a mechanistic and clinical effect basis but does not preclude subtle differences potentially impacting specific patients.

No safety signal divergence from Herceptin has been reported, but rare side effects or long-term cardiac outcomes require ongoing pharmacovigilance. Manufacturer incentives, commercial competition, and regulatory frameworks supporting biosimilar approvals may influence interpretation and reporting, meriting cautious, balanced scrutiny.

Why it matters

The approval of Herwenda broadens treatment options for patients with HER2-positive breast and gastric cancers in the EU, potentially facilitating access through biosimilar competition. As trastuzumab is an established life-prolonging therapy, ensuring effective and affordable biosimilars could impact public health outcomes, healthcare system sustainability, and patient affordability.

Understanding the rigorous evaluation standards applied by regulatory bodies helps inform patient confidence and clinical decision-making. However, awareness of inherent uncertainties in substituting biosimilars is important for clinicians, patients, and policymakers to maintain vigilance and ensure optimal outcomes.

What to verify next

  • Monitor updates from independent clinical studies or real-world evidence assessing long-term safety and effectiveness of Herwenda in varied populations.
  • Investigate cost and reimbursement policies across EU member states to gauge actual patient access impact.
  • Review pharmacovigilance data published post-authorization concerning adverse events and potential immunogenicity issues specific to Herwenda.
  • Compare health technology assessments and clinical guidelines addressing biosimilar trastuzumab usage to detect institutional variation or cautionary recommendations.

Readers are encouraged to consult the European Medicines Agency’s official European Public Assessment Report (EPAR) on Herwenda for the complete and detailed regulatory and scientific data supporting this summary.

Source & verification

Primary source: What's new · November 10, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…